Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors Whisenant, J., Beckermann, K., Borghaei, H., Owonikoko, T., Patel, J., Berry, L., Shyr, Y., Harrow, K., Liang, C., Holzhausen, A., Selvaggi, G., Wakelee, H., Horn, L. ELSEVIER SCIENCE INC. 2019: S445–S446

View details for Web of Science ID 000492162202249